By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Both the CEOs of Moderna and Pfizer said a booster dose of their respective COVID-19 vaccines could be required as soon as September for those who were among the earliest vaccinated. During an Axios ...

Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15. Lyme disease is a bacterial ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...